These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 31156616)

  • 1. CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade.
    Garcia-Perez JE; Baxter RM; Kong DS; Tobin R; McCarter M; Routes JM; Verbsky J; Jordan MB; Dutmer CM; Hsieh EWY
    Front Immunol; 2019; 10():998. PubMed ID: 31156616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.
    Bakacs T; Mehrishi JN
    Immunobiology; 2015 May; 220(5):624-5. PubMed ID: 25638260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.
    Lo B; Zhang K; Lu W; Zheng L; Zhang Q; Kanellopoulou C; Zhang Y; Liu Z; Fritz JM; Marsh R; Husami A; Kissell D; Nortman S; Chaturvedi V; Haines H; Young LR; Mo J; Filipovich AH; Bleesing JJ; Mustillo P; Stephens M; Rueda CM; Chougnet CA; Hoebe K; McElwee J; Hughes JD; Karakoc-Aydiner E; Matthews HF; Price S; Su HC; Rao VK; Lenardo MJ; Jordan MB
    Science; 2015 Jul; 349(6246):436-40. PubMed ID: 26206937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine LRBA deficiency causes CTLA-4 deficiency in Tregs without progression to immune dysregulation.
    Burnett DL; Parish IA; Masle-Farquhar E; Brink R; Goodnow CC
    Immunol Cell Biol; 2017 Oct; 95(9):775-788. PubMed ID: 28611475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Phenotypes and Immunological Characteristics of 18 Egyptian LRBA Deficiency Patients.
    Meshaal S; El Hawary R; Adel R; Abd Elaziz D; Erfan A; Lotfy S; Hafez M; Hassan M; Johnson M; Rojas-Restrepo J; Gamez-Diaz L; Grimbacher B; Shoman W; Abdelmeguid Y; Boutros J; Galal N; El-Guindy N; Elmarsafy A
    J Clin Immunol; 2020 Aug; 40(6):820-832. PubMed ID: 32506362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
    Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA
    J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exaggerated follicular helper T-cell responses in patients with LRBA deficiency caused by failure of CTLA4-mediated regulation.
    Alroqi FJ; Charbonnier LM; Baris S; Kiykim A; Chou J; Platt CD; Algassim A; Keles S; Al Saud BK; Alkuraya FS; Jordan M; Geha RS; Chatila TA
    J Allergy Clin Immunol; 2018 Mar; 141(3):1050-1059.e10. PubMed ID: 28601686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary manifestations of immune dysregulation in CTLA-4 haploinsufficiency and LRBA deficiency.
    Krone KA; Winant AJ; Vargas SO; Platt CD; Bartnikas LM; Janssen E; Lillehei C; Lee EY; Fishman MP; Casey A
    Pediatr Pulmonol; 2021 Jul; 56(7):2232-2241. PubMed ID: 33710794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes.
    Gámez-Díaz L; Grimbacher B
    Biomed J; 2021 Aug; 44(4):400-411. PubMed ID: 34384744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons from CTLA-4 deficiency and checkpoint inhibition.
    Lo B; Abdel-Motal UM
    Curr Opin Immunol; 2017 Dec; 49():14-19. PubMed ID: 28806575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What did we learn from CTLA-4 insufficiency on the human immune system?
    Mitsuiki N; Schwab C; Grimbacher B
    Immunol Rev; 2019 Jan; 287(1):33-49. PubMed ID: 30565239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept for treatment-refractory pediatric CTLA4-haploinsufficiency.
    Lanz AL; Riester M; Peters P; Schwerd T; Lurz E; Hajji MS; Rohlfs M; Ley-Zaporozhan J; Walz C; Kotlarz D; Klein C; Albert MH; Hauck F
    Clin Immunol; 2021 Aug; 229():108779. PubMed ID: 34116213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations.
    Hou TZ; Verma N; Wanders J; Kennedy A; Soskic B; Janman D; Halliday N; Rowshanravan B; Worth A; Qasim W; Baxendale H; Stauss H; Seneviratne S; Neth O; Olbrich P; Hambleton S; Arkwright PD; Burns SO; Walker LS; Sansom DM
    Blood; 2017 Mar; 129(11):1458-1468. PubMed ID: 28159733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifocal gastric adenocarcinoma in a patient with LRBA deficiency.
    Bratanič N; Kovač J; Pohar K; Trebušak Podkrajšek K; Ihan A; Battelino T; Avbelj Stefanija M
    Orphanet J Rare Dis; 2017 Jul; 12(1):131. PubMed ID: 28720148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab).
    Fietz S; Zarbl R; Niebel D; Posch C; Brossart P; Gielen GH; Strieth S; Pietsch T; Kristiansen G; Bootz F; Landsberg J; Dietrich D
    Cancer Immunol Immunother; 2021 Jun; 70(6):1781-1788. PubMed ID: 33196890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the levels of CTLA-4-dependent biological defects in patients with LRBA deficiency and CTLA-4 insufficiency.
    Catak MC; Akcam B; Bilgic Eltan S; Babayeva R; Karakus IS; Akgun G; Baser D; Bulutoglu A; Bayram F; Kasap N; Kiykim A; Hancioglu G; Kokcu Karadag SI; Kendir Demirkol Y; Ozen S; Cekic S; Ozcan D; Edeer Karaca N; Sasihuseyinoglu AS; Cansever M; Ozek Yucel E; Tamay Z; Altintas DU; Aydogmus C; Celmeli F; Cokugras H; Gulez N; Genel F; Metin A; Guner SN; Kutukculer N; Keles S; Reisli I; Kilic SS; Yildiran A; Karakoc-Aydiner E; Lo B; Ozen A; Baris S
    Allergy; 2022 Oct; 77(10):3108-3123. PubMed ID: 35491430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive comparison between 222 CTLA-4 haploinsufficiency and 212 LRBA deficiency patients: a systematic review.
    Jamee M; Hosseinzadeh S; Sharifinejad N; Zaki-Dizaji M; Matloubi M; Hasani M; Baris S; Alsabbagh M; Lo B; Azizi G
    Clin Exp Immunol; 2021 Jul; 205(1):28-43. PubMed ID: 33788257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preponderance of
    Siggs OM; Russell A; Singh-Grewal D; Wong M; Chan P; Craig ME; O'Loughlin T; Stormon M; Goodnow CC
    Front Immunol; 2019; 10():1544. PubMed ID: 31396201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterozygous
    Mahat U; Ambani NM; Rotz SJ; Radhakrishnan K
    Pediatr Hematol Oncol; 2021 Oct; 38(7):658-662. PubMed ID: 33900894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.
    Schubert D; Bode C; Kenefeck R; Hou TZ; Wing JB; Kennedy A; Bulashevska A; Petersen BS; Schäffer AA; Grüning BA; Unger S; Frede N; Baumann U; Witte T; Schmidt RE; Dueckers G; Niehues T; Seneviratne S; Kanariou M; Speckmann C; Ehl S; Rensing-Ehl A; Warnatz K; Rakhmanov M; Thimme R; Hasselblatt P; Emmerich F; Cathomen T; Backofen R; Fisch P; Seidl M; May A; Schmitt-Graeff A; Ikemizu S; Salzer U; Franke A; Sakaguchi S; Walker LSK; Sansom DM; Grimbacher B
    Nat Med; 2014 Dec; 20(12):1410-1416. PubMed ID: 25329329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.